Senior managers invest $200 million in Baxter:
This article was originally published in Clinica
Executive Summary
In a move designed to "align the interests of managers and shareholders", 142 senior managers of the Deerfield, Illinois-based healthcare company have taken out loans averaging $1.4 million each to buy a total of 3.1 million Baxter shares. The investment plan repeats a similar exercise of five years ago and managers only receive the full value of any gains after three years.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.